


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application

### Listing of Claims

1. - 20. (Cancelled)


21. (Currently amended) A compound of formula I:



in free or salt or solvate form, where

R<sup>1</sup> is hydroxy and R<sup>2</sup> is hydrogen;

G is a group having the formula Ib:



C~C denotes C=C or CH-CH;

R<sup>7</sup> and R<sup>8</sup> are both hydrogen;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>10</sub> alkyl, or R<sup>9</sup> and R<sup>10</sup> together form a C<sub>3</sub>-C<sub>10</sub> cycloalkyl or C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, and in either case wherein R<sup>9</sup> and R<sup>10</sup> are optionally substituted by C<sub>1</sub>-C<sub>10</sub> alkyl; and

R<sup>11</sup> is a C<sub>3</sub>-C<sub>15</sub> carbocyclic group or C<sub>1</sub>-C<sub>10</sub> alkyl substituted by a C<sub>3</sub>-C<sub>15</sub> carbocyclic group.

22. (Previously presented) The compound according to claim 21, wherein:

R<sup>1</sup> is hydroxy and R<sup>2</sup> is hydrogen;

C~C denotes C=C or CH-CH;

R<sup>7</sup> and R<sup>8</sup> are both hydrogen;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl, or

R<sup>9</sup> and R<sup>10</sup> together form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkenyl, and in either case wherein R<sup>9</sup>

and R<sup>10</sup> are optionally substituted by C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sup>11</sup> is a C<sub>3</sub>-C<sub>10</sub> carbocyclic or C<sub>1</sub>-C<sub>10</sub> alkyl substituted by a C<sub>3</sub>-C<sub>10</sub> carbocyclic group.

23. (Previously presented) The compound according to claim 22, wherein R<sup>11</sup> is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl.

24. (Previously presented) The compound according to claim 22, wherein R<sup>11</sup> is a C<sub>1</sub>-C<sub>10</sub> alkyl substituted by an unsaturated C<sub>5</sub>-C<sub>8</sub> carbocyclic group.

25. (Previously presented) The compound according to claim 21 that is:

5-[R-2-(1S,2S-2-Cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;

5-[R-2-(1R,2R-2-cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;

5-[R-2-(1R,2R-bicyclopentyl-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; or

5-[R-2-(1R,2R-2-Benzylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one.

26. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21.

27. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and at least one pharmaceutically acceptable carrier.


28. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and a therapeutically effective amount of another drug substance selected from the group consisting of an anti-inflammatory, a bronchodilator, an antihistamine, an immunosuppressive and an anti-tussive.

29. (Cancelled).

30. (Previously presented) A method of treating a patient with obstructive or inflammatory airways disease by administering a therapeutically effective amount of at least one compound according to claim 21.

31. (Currently amended) A process for the preparation of a compound of claim 21 in free or salt or solvate form comprising:


(A) reacting a compound of formula II:



or a protected form thereof wherein  $R^1$  and  $R^2$  are as defined in claim 21, with a compound of formula III:



where G is a group of formula Ib:




or a protected form thereof wherein  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined in claim 21;  
and

(B) recovering the resultant compound of formula I in free or salt ~~or solvate~~-form.

32. (Currently amended) A process for the preparation of a compound of claim 21 in free or salt ~~or solvate~~-form comprising:

(A) reducing a compound of formula IV:



or a protected form thereof wherein  $R^1$ ,  $R^2$  and G are as defined in claim 21, to convert the indicated keto group into  $-CH(OH)$ ; and

(B) recovering the resultant compound of formula I in free or salt ~~or solvate~~-form.

33. (New) The method of claim 30 wherein the obstructive or inflammatory airways disease is asthma, adult/acute respiratory distress syndrome, chronic obstructive pulmonary or airways disease, chronic bronchitis or dyspnea associated therewith, emphysema, exacerbation of airways hyperreactivity consequent to other drug therapy, bronchitis or pneumoconiosis.